HomeTOP STORIESNovo Nordisk, Eli Lilly face first major obesity drug rival in China... Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide By rogerjudd June 30, 2025 FacebookTwitterPinterestWhatsApp Post Content Previous articleSEALSQ finalizes strategic investment in WeCan Group with 28.30% equity stake acquisitionNext articleApple supplier Lens Technology seeks up to $606M in Hong Kong listing latest articles The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds explore more The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds
